MRNA - Why Pharma Giant Merck's Shares Are Shooting Higher Today | Benzinga
Merck & Company, Inc. (NYSE: MRK) Q3 sales reached $15.962 billion, up 7% Y/Y, beating the consensus of $15.320 billion, reflecting sustained growth in Oncology and Vaccines.
Lagevrio Q3 sales jumped 51% Y/Y to $640 million, and GARDASIL / GARDASIL 9 sales grew 16% to $2.585 billion.
Excluding Lagevrio (COVID-19 treatment), sales growth was 6%; excluding Lagevrio and the impact of foreign exchange, growth was 8%.
Pharmaceutical sales increased by 11% to $14.26 billion, primarily due to higher sales ...